Dr. Kanter is a co-PI on two large implementation trails in sickle cell disease as well as a site PI for several sponsored research studies. Dr. Kanter is interested in identifying novel methods to enhance access to care for individuals living with sickle cell disease and for working to develop novel therapeutics to improve care outcomes. Dr. Kanter is part of the NHLBI sickle cell disease advisory panel and the American Society of Hematology government relations committee.